Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar will feature a live question-and-answer session and will be led by Founder, President and CEO Maria Maccecchini, Ph.D. The discussion will cover recent progress, ongoing clinical programs, and upcoming milestones, including the fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with top-line data and regulatory submissions expected in 2027.
The announcement comes at a critical time for Annovis as it advances its lead drug candidate, buntanetap (formerly posiphen), an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43. By targeting these proteins through a specific RNA-targeting mechanism, buntanetap aims to address the underlying causes of neurodegeneration, potentially halting disease progression and improving cognitive and motor functions in patients with Alzheimer's and Parkinson's diseases.
In addition to the Phase 3 AD trial, Annovis plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. The company's Parkinson's disease (PD) open-label study is already underway, and discussions are ongoing regarding the initiation of a Parkinson's disease dementia program. These initiatives underscore Annovis's commitment to expanding its pipeline and addressing the significant unmet medical needs in neurodegenerative disorders.
The webinar is expected to provide investors and stakeholders with deeper insights into the company's strategic direction and the potential impact of buntanetap on the treatment landscape for AD and PD. With the global burden of Alzheimer's and Parkinson's diseases rising, the development of disease-modifying therapies like buntanetap is of paramount importance. Annovis's progress in clinical trials could offer new hope for millions of patients and their families, making the upcoming milestones highly anticipated.
For more information about the webinar and to access the full press release, interested parties can visit https://ibn.fm/mls3F. Additionally, the latest news and updates on Annovis Bio are available in the company's newsroom at https://ibn.fm/ANVS.
